Investigation of Drug-drug Interaction Between Clopidogrel and Fluoxetine
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
Clopidogrel is a platelet aggregation inhibitor witch prevents thrombotic events in patients
with atherosclerotic vascular disease. To date, 4 to 30 % of patients are considered as poor,
low or non-responder to this therapeutic. However, drug-drug interactions may lead to
decrease the clopidogrel responsiveness. Many arguments are in support to a drug-drug
interaction between clopidogrel and fluoxetine (selective serotonin reuptake inhibitor). On
the pharmacokinetic level, fluoxetine inhibits the cytochroms involved in the production of
clopidogrel active metabolite. On the pharmacodynamic level fluoxetine could increase the
risk of hemorrhage by inhibiting the serotonin platelet reuptake and thus enhance the
antiplatelet effect of clopidogrel.
The purpose of this study is to investigate the influence of fluoxetine on pharmacokinetic
and pharmacodynamic of clopidogrel.